Galmed Pharmaceuticals (GLMD) Announces Proposed Offering of Ordinary Shares
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
Galmed Pharmaceuticals Announces Proposed Offering of Ordinary Shares
February 16, 2021 6:48 AM ESTTEL AVIV, Israel, Feb. 16, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases, today announced that it is commencing an underwritten public offering of its Ordinary Shares (the "Offering"). All of the shares to be sold in the Offering will be sold by Galmed, subject to customary closing conditions. In addition, Galmed intends to grant the underwriter for the Offering a 30-day option to purchase up to an additional 15% of the number of its Ordinary Shares offered in... More
